The Department of Health enjoins all concerned stakeholders to provide position papers, recommendations and other inputs on the draft Executive Order to impose Maximum Retail Price and Maximum Wholesale Price on COVID-19 Drugs and Medicines
The Department of Health enjoins all concerned stakeholders to provide position papers, recommendations and other inputs on the draft Administrative Order that sets the standards on the implementation of the Antimicrobial Stewardship Program in the primary care setting.
The Department of Health will conduct series of virtual trainings on Antimicrobial Stewardship this August and October 2022.
After three long years and five virtual policy dialogues, the Department of Health (DOH), its partner agencies and offices and the patient support groups and civil society organizations finally convened again face to face during the 16th Policy Dialogue on Universal Healthcare and Access to Medicines held on June 9, 2022 at Cocoon Boutique Hotel, Quezon City.
The Department of Health informs all DOH and CHD officials, Philhealth and DOH hospitals and health facilities on the Exemption from Import Duties, Taxes and Other Fees for the Procurement, continue reading : DOH clarifies exemptions of COVID-19 Vaccines not listed under the latest PNF.
The Department of Health will hold a consultative meeting via Webex platform on 08 June 2022, 2:00-4:00 PM to get the comments and feedback of medical centers, hospitals, sanitaria and specialty hospitals on the newly-developed COVID-19 medicines tracker.
The Department of Health-Pharmaceutical Division (DOH-PD) conducted a face-to-face Program Implementation Review (PIR) and updates on the different programs of the Pharmaceutical Division in Coron Palawan last April 26-28, 2022 after two years of restrictions from the COVID-19 pandemic.
The DOH Pharmaceutical Division expresses its gratitude to the leadership and concern for poor and vulnerable Filipino patients shown by President Rodrigo Duterte with the passage of two landmark Executive Orders which set maximum retail price to 120 high cost medicines.
A successful initial collaboration of the DOH Pharamceutical Division – Medical Device Unit spearheaded by Dir. Anna Melissa S. Guerrero, MD, MPH (HTA) and Dr. Constante Caluya III, MBA and their Expert Advisory Committee for medical devices and supplies led by Dr. Ronaldo H. Estacio, together with the Health Technology Assessment Division headed by Ms. Anne Julienne Genuino-Marfori, RPh, MSc and their Health Technology Assessment Council chaired by Dr. Marita V. Tolentino-Reyes.
DOH request its NCR hospitals to facilitate patient recruitment for clinical trial.